• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Petros Pharmaceuticals Inc (NQ: PTPI )

    0.3400 +0.0073 (+2.19%)
    Streaming Delayed Price Updated: 1:34 PM EDT, Sep 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 16,081
    Open 0.3289
    Bid (Size) 0.3300 (37)
    Ask (Size) 0.3387 (2)
    Prev. Close 0.3327
    Today's Range 0.3289 - 0.3401
    52wk Range 0.2821 - 2.505
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    Via ACCESSWIRE
    PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
    PTPI stock results show that Petros Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -76.06%
    -76.06%
    1 Month
    -3.95%
    -3.95%
    3 Month
    -34.49%
    -34.49%
    6 Month
    -79.14%
    -79.14%
    1 Year
    -85.75%
    -85.75%

    More News

    Read More
    Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
    Via ACCESSWIRE
    Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
    Via ACCESSWIRE
    EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says
    Via Benzinga
    Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA
    Via ACCESSWIRE
    Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
    Via ACCESSWIRE
    Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Why Broadcom Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch
    Via ACCESSWIRE
    PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
    From 23andMe, Inc.
    Via GlobeNewswire
    Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
    Via ACCESSWIRE
    Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
    Via ACCESSWIRE
    Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
    Via ACCESSWIRE
    Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
    Via ACCESSWIRE
    BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc
    Via TheNewswire.com
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.